A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Seagen Inc.
- 入组人数
- 195
- 试验地点
- 14
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute myeloid leukemia (AML). The MTD will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be assessed.
详细描述
This study will explore SGN-CD33A as a monotherapy and in combination with a hypomethylating agent (HMA; i.e., azacitidine or decitabine). Initial study treatment with SGN-CD33A includes a maximum of 2 cycles of treatment for monotherapy and 4 cycles for combination cohorts. Patients who achieve documented CR or CRi (Monotherapy) or clinical benefit (Combination) during the first part of the study are eligible to continue treatment.
Additional monotherapy cohorts may include patients with relapsed acute promyelocytic leukemia, relapsed patients with nucleophosmin-1 gene mutation (absence of fms-like tyrosine kinase 3 mutation) (NPM1-mutated, FLT-3 wild type), alternate dosing schedules (fractionated dosing on Days 1 and 4), treatment naive patients with AML who declined intensive therapy, and patients who have relapsed after post-allogeneic stem cell transplant.
Patients in the combination cohort will be treated with azacitidine or decitabine per institutional practice prior to SGN-CD33A dosing. Expansion cohorts may be added for further evaluation of safety, pharmacokinetics, pharmacodynamics, and antitumor activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute myeloid leukemia, positive for CD33
- •Eastern Cooperative Oncology Group status of 0 or 1
- •Adequate baseline renal and hepatic function
- •Central venous access
- •Either achieved complete remission (greater than 12 weeks in duration) with initial induction/consolidation and have experienced relapse of disease or declined treatment with high-dose induction/consolidation
- •Bone marrow blasts greater than or equal to 5% for relapsed patients, or greater than or equal to 20% for untreated patients
排除标准
- •Inadequate lung function
- •Prior allogeneic stem cell transplant, except for a specific cohort
- •High-dose chemotherapy within 4 weeks of study drug
- •Antileukemia treatment within 14 days of study drug (other than hydroxyurea or 6-mercaptopurine)
研究组 & 干预措施
SGN-CD33A + HMA
SGN-CD33A with hypomethylating agent
干预措施: HMA (Drug)
SGN-CD33A + HMA
SGN-CD33A with hypomethylating agent
干预措施: SGN-CD33A (Drug)
SGN-CD33A Monotherapy
SGN-CD33A
干预措施: SGN-CD33A (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: Through 1 month following last dose
Incidence of laboratory abnormalities
时间窗: Through 1 month following last dose
次要结局
- Rate of complete remission(Up to 3 months)
- Incidence of antitherapeutic antibodies(Through 1 month following last dose)
- Relapse-free survival(Up to approximately 3 years)
- Overall survival(Up to approximately 3 years)
- Blood concentrations of SGN-CD33A and metabolites(Through 3 weeks after dosing)
- Duration of complete remission(Up to approximately 3 years)